Leqembi is an infusion therapy that targets and removes the beta-amyloid plaque that builds up in the brains of Alzheimer's ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

The new findings center on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

Latest Alzheimer's drug shown less effective in females than males. ScienceDaily . Retrieved March 20, 2025 from www.sciencedaily.com / releases / 2025 / 03 / 250318175021.htm ...